SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery
SURGE Therapeutics, a biotech company pioneering the delivery of immunotherapy during cancer surgery, announced today the completion of a $32 million Series B financing led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech.
When someone has a tumor localized to one part of the body, the traditional treatment is pretty simple: use surgery to cut it out. But such surgeries aren’t perfect. Tumors can grow back, often bolstered by a suppression of the immune system that can follow surgery.
Immunotherapy during surgery? Surge Therapeutics nabs $32M to expand clinical plans after first dosing
Weeks ago, Surge Therapeutics marked what CEO Michael Goldberg hopes will go down in history as a turning point in cancer care: the first time a patient received an immunotherapy, in the form of a hydrogel, at the site of their tumor during surgery.
SURGE Therapeutics Receives FDA Clearance of IND Application to Initiate Phase 1/2a Study of Intraoperative Immunotherapy in Bladder Cancer
SURGE Therapeutics (SURGE) announced today that the U.S. Food & Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to proceed with a Phase 1/2a study of its intraoperative immunotherapy, SURGERx with resiquimod (STM-416), for prevention of recurrence and/or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) who were previously diagnosed with high-grade disease and experience recurrence.
SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery
Funding will be used to accelerate development of the SURGE™ intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its first two programs.
Surge Therapeutics has raised money to take its extended-release biodegradable hydrogel into the clinic, reeling in $26 million to test its belief that implanting the scaffolds after surgery will improve outcomes in solid tumor patients.
Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery
Every year, millions of cancer patients undergo surgery to get their tumors removed. But while resection can stave off cancer for some time, as many as 40% of patients would eventually see their cancer return — and succumb to the disease.
Post-surgical recurrence and metastasis account for 90 percent of cancer-related deaths, something Dr. Michael Goldberg, founder and CEO of newly debuted SURGE Therapeutics, knows all too well.
Surge Therapeutics Inc. landed $26 million in funding through a series A fundraising round to accelerate development of its intraoperative immunotherapy hydrogel.
Cancers are like garden weeds. Even after the surgical removal of a tumor, cancer-cell stragglers can grow back and overrun the body. Surgery is the most common intervention for tumors, but it’s by no means a cure—about 40% of the 9 million people around the world who undergo the procedure every year experience a cancer comeback within 5 years.
A scientist who trained under renowned chemical engineer Bob Langer and Nobel Prize-winning Biogen Inc. co-founder Phillip Sharp has ideas about how to transform cancer treatment.
Surge Therapeutics' hydrogel is engineered to deliver a cancer immunotherapy. Rather than replace surgery, CEO Michael Goldberg says the hydrogel could supplement this standard of care for solid tumors. The startup's Series A financing will support the technology's first test in humans.